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Background: Microvascular invasion (MiVI) is a histological feature of intrahepatic
cholangiocarcinoma (ICC) that may be associated with biological behavior. We sought
to investigate the impact of MiVI on long‐term survival of patients undergoing
curative‐intent resection for ICC.
Methods: A total of 1089 patients undergoing curative‐intent resection for ICC were
identified. Data on clinicopathological characteristics, disease‐free survival (DFS), and
overall survival (OS) were compared among patients with no vascular invasion (NoVI),
MiVI, and macrovascular invasion (MaVI).
Results: A total of 249 (22.9%) patients had MiVI, while 149 (13.7%) patients had
MaVI (±MiVI). MiVI was associated with higher incidence of perineural, biliary and
adjacent organ invasion, and satellite lesions (all P < 0.01). On multivariable analysis,
MiVI was an independent risk factor of DFS (hazard ratios [HR] 1.5; 95%confidence
intervals [CI], 1.3‐1.9; P < 0.001), but not OS (HR 1.1; 95%CI, 0.9‐1.3; P = 0.379).
While MiVI and MaVI patients had similar DFS (median, MiVI 14.0 vs MaVI 12.0
months, HR 0.9; 95%CI, 0.7‐1.2; P = 0.377), OS was better among MiVI patients
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(median, MiVI 39.0 vs MaVI 21.0 months, HR 0.7; 95%CI, 0.5‐0.8; P = 0.002). Whereas
nodal metastasis, R1 margin, and postoperative morbidity were associated with early
death (≤18 months) among patients with MiVI, only nodal metastasis was associated
with late (>18 months) prognosis.
Conclusions: Roughly 1 out of 5 patients with resected ICC had MiVI. MiVI was
associated with advanced tumor characteristics and a higher risk of tumor
recurrence.
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1 | INTRODUCTION
Intrahepatic cholangiocarcinoma (ICC) is the second most common
primary liver tumor after hepatocellular carcinoma (HCC), and its
incidence and mortality are increasing worldwide.1,2 Surgical
resection is currently the only potentially curative treatment
option for patients with ICC.3 However, long‐term survival after
curative resection among patients with ICC is disappointing.
Specifically, 5‐year survival after resection has been reported to
be only 20%‐35% with over two‐thirds of patients experiencing
recurrence.4-6
The vascular invasion has been identified as one of the
strongest risk factors contributing to recurrence and death of
patients with ICC after surgery.7,8 The 7th and 8th editions of the
American Joint Committee on Cancer (AJCC) staging manual
incorporate vascular invasion within the T category designation.9
Macrovascular invasion (MaVI) is defined as tumor invasion into a
major vessel that can be identified by radiological imaging or
macroscopic examination. In contrast, the diagnosis of microvas-
cular invasion (MiVI) is largely dependent on histological examina-
tion.10 Generally, MiVi has been defined as the presence of tumor
emboli in a portal radical vein, large capsule vessel, or in a vascular
space lined by endothelial cells.10 MiVI has been extensively
studied and reported to be a strong indicator of worse outcomes
among patients with hepatocellular carcinoma (HCC) after resec-
tion or liver transplantation.10-17 In fact, MiVI is now recognized as
the main cause of MaVI and intrahepatic metastasis among
patients with HCC.18 In turn, HCC with histologically confirmed
MiVI have a high risk of recurrence after resection and several
studies have suggested that adjuvant therapies, such as transar-
terial chemotherapy and embolization19,20 and sorafenib,21 may
improve the outcome of these patients. In contrast, the potential
impact of MiVI on the long‐term outcome of patients with ICC has
not been well investigated. As such, the objective of the present
study was to define the clinical impact of MiVI on the prognosis of
patients after curative‐intent resection of ICC using a large, multi‐
institutional, international database.
2 | PATIENTS AND METHODS
2.1 | Study cohort
Patients undergoing resection with curative intent for ICC from 1990
to 2015 were collected from a multi‐institutional database that
included 14 major hepatobiliary centers in the USA, Europe,
Australia, and Asia (The Ohio State University, Columbus, Ohio;
Johns Hopkins University, Baltimore, Maryland; Emory University,
Atlanta, Georgia; Stanford University Medical Center, Stanford,
California; University of Virginia Health System, Charlottesville,
Virginia and Ottawa General Hospital, Ottawa, Canada, Eastern
Hepatobiliary Surgery Hospital, Shanghai, China; Yokohama City
University, Yokohama, Japan; Royal Prince Alfred Hospital, Sydney,
Australia; Fundeni Clinical Institute, Bucharest, Romania; Beaujon
Hospital, Clichy, France; Curry Cabral Hospital, Lisbon, Portugal; San
Raffaele Hospital, Milan, Italy; and Erasmus University Medical
Centre Rotterdam, Rotterdam, The Netherlands). The diagnosis of
ICC was histologically confirmed in all cases. Resection with curative
intent was defined as macroscopic removal of all tumors (R0 or R1
resection). Patients who underwent palliative or R2 resection,
ablation, or intra‐arterial therapy and patients with extrahepatic
metastasis were excluded. The Institutional Review Boards of each
participating institution approved the study.
2.2 | Data collection and follow‐up
Preoperative variables, including standard demographic, clinicopatho-
logical, and tumor‐related characteristics, were collected using a
standardized data sheet. All resected specimens were subjected to
histological analysis and were evaluated for tumor size, number,
morphology, differentiation, margin, vascular, biliary and perineural
invasion, lymph node status, as well as adjacent organ invasion. MaVI
was defined as invasion of the tumor into a major vessel that was
identified during the macroscopic examination or radiographic
imaging; MiVI was defined as tumor invasion of hepatic veins, portal
system, and lymphatic ducts that were visible only on microscopy.10,15
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An R0 resection was defined as a minimum margin length of >1mm;
the microscopic presence of tumor at the margin or a minimum margin
length of ≤1mmwas designated as an R1 resection. Pathologic staging
was assigned according to the 8th edition American Joint Committee
on Cancer (AJCC) staging guidelines.9 Details of the operation were
documented and collected, including resection mode, lymphadenect-
omy, operation time, and intraoperative blood loss.
After discharge, all patients were regularly followed with serum
carbohydrate antigen 19‐9 (CA19‐9), carcinoembryonic antigen (CEA),
and imaging studies, including abdominal ultrasonography, computed
tomography and/or magnetic resonance imaging (MRI) until the death
of the patient or the end of the study. In the present study, the primary
endpoints were overall survival (OS) and disease‐free survival (DFS). OS
was defined as the time duration from the date of initial resection to
patient death or the end of the study. DFS was defined as the time
duration from the date of initial surgery to tumor recurrence.
Recurrence was defined as suspicious imaging findings or biopsy‐
proven tumor. The site of recurrence was categorized as intrahepatic
and/or extrahepatic. Treatments of recurrence were tailored according
to the tumor burden and general condition of the patient. Curative‐
intent therapies for recurrence included surgical re‐resection, ablation,
or combined resection plus ablation.
2.3 | Statistical analysis
Continuous variables were expressed as medians with interquartile
ranges; student t test or the Mann‐Whitney U test were used for
statistical analysis as appropriate. Categorical variables were
expressed as number and percentages and compared with χ2 test
or Fisher's exact test. Survival was analyzed by the life table and
Kaplan‐Meier method and compared with the logrank test. Factors
associated with OS and DFS were identified using univariate and
multivariable Cox proportional hazards regression models. Hazard
ratios (HR) and 95% confidence intervals (CI) were estimated. The
variables with a P value less than 0.05 on univariate analysis were
included in the multivariable models. A two‐tailed P value less than
0.05 was considered statistically significant. Statistical analyses were
performed using SPSS version 21.0 (IBM SPSS Inc, Chicago, IL).
3 | RESULTS
3.1 | Baseline characteristics
Among 1,089 patients who underwent curative‐intent resection for ICC,
149 (13.7%) had MaVI with or without MiVI, while 249 (22.9%) had
MiVI on histological examination without evidence of MaVI. The
clinicopathological characteristics and surgery details among patients
with no vascular invasion (NoVI) vs MiVI vs MaVI were compared
(Table 1). Although tumor size and number, as well as serum markers (ie
Ca19‐9 and CEA) were not different among the three groups, tumors
with either macro‐ or MiVI had a higher incidence of perineural, biliary
and adjacent organ invasion, as well as the presence of satellite lesions
(all P < 0.01). In addition, patients with vascular invasion were more
likely to have advanced AJCC T disease, lymph node metastasis, and
poor tumor differentiation vs patients with NoVI (all P <0.05). Although
patients with macro‐ or MiVI were more likely to undergo a major
hepatectomy and concomitant lymphadenectomy (both P <0.01), the
incidence of an R0 resection was lower among patients with vs without
vascular invasion (MaVI 79.2%, MiVI 80.3% vs NoVI 92.0%; P < 0.001).
Among patients who had the vascular invasion, patients with MaVI had
a higher incidence of adjacent organ invasion (13.4% vs 5.6%), nodal
metastasis (37.7% vs 22.9%) compared with patients who had MiVI (all
P <0.05). In contrast, tumor size, number, as well as the incidence of the
perineural and biliary invasion were equivalent among patients with
MaVI vs MiVI. The frequency of adjuvant chemo‐ and radiotherapy was
comparable among patients with MiVI and MaVI; of note, the use of
chemotherapy among these patients was higher than patients without
vascular invasion (MiVI 38.3%, MaVI 39.8% vs NoVI 24.7%; P < 0.001).
3.2 | Survival of patients stratified by vascular
invasion
After a median follow‐up of 35 (range 3‐211) months, a total of 553
(50.8%) patients had died. In examining the entire cohort, 1‐, 3‐ and
5‐year OS was 78.8%, 49.9%, and 38.7%, respectively, while 1‐, 3‐
and 5‐year DFS was 57.4%, 35.2% and 19.5%, respectively. Of note,
patients with MiVI had a better OS compared with patients who had
MaVI (median OS, MiVI 39.0 vs MaVI 21.0 months; HR 0.7; 95%CI,
0.5‐0.8; P = 0.002), which was comparable with patients who had
NoVI (median OS, MiVI 39.0 vs NoVI 45.0 months; HR 1.2; 95% CI,
0.9‐1.5; P = 0.194) (Figure 1A). In contrast, patients with MiVI had a
similar DFS as patients with MaVI (median DFS, MiVI 14.0 vs MaVI
12.0 months, HR 0.9; 95% CI, 0.7‐1.2; P = 0.377), which was worse
than patients with NoVI (median DFS, MiVI 14.0 vs NoVI 21.0
months, HR 1.5; 95%CI 1.3‐1.9; P < 0.001) (Figure 1B).
On multivariable analysis, after taking into account competing
risk factors, MaVI (HR 1.5; 95%CI, 1.1‐1.9; P = 0.005), rather than
MiVI (HR 1.1; 95%CI, 0.9‐1.3; P = 0.379), was associated with worse
long‐term survival (Table 2). In contrast, both MaVI (HR 1.4; 95%CI,
1.0‐1.8; P = 0.022) and MiVI (HR 1.6; 95%CI, 1.3‐2.0; P < 0.001),
tumor size, number, and differentiation, as well as lymph node status
were correlated with risk of tumor recurrence (Table 3).
3.3 | Recurrence and treatments
During follow‐up, 729 (66.9%) patients experienced tumor recurrence
after surgery. Among patients who recurred, patients with MaVI or MiVI
were more likely to develop extrahepatic recurrence than patients with
NoVI (MaVI 42.2%, MiVI 41.8% vs NoVI 31.6%; P =0.003) (Figure 2A).
The recurrence pattern was similar among patients with MiVI vs MaVI
(Figure 2A). Among 626 patients who were treated for recurrence,
patients with MiVI were more likely to undergo a subsequent curative‐
intent treatment compared with patients with MaVI (17.7% vs 7.0%;
P= 0.033). The utilization of repeat curative‐intent treatments for
recurrences was similar among patients with NoVI and MiVI who
recurred (17.7% vs 12.1%; P = 0.082) (Figure 2B). Perhaps not
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surprisingly, median OS after the first recurrence among patients with
MaVI (8.0 months) was worse than patients with MiVI (17.0 months) or
NoVI (13.0 months) (P <0.001).
3.4 | Survival of patients with MiVI: Early death
versus long‐term survival
In examining OS of patients with MiVI vs MaVI, long‐term survival
was initially generally similar, yet became divergent beginning
roughly around 18 months after surgery (cumulative survival rate
at 18 months, MiVI 63.9% vs MaVI 55.5%; P = 0.01) (Figure 1A).
Overall, 79 patients with MiVI died within 18 months after initial
surgery (early death), whereas 118 patients survived longer than
18 months (long‐term survival). Patients who died within 18
months after initial surgery were more likely to have multiple
tumors (26.6% vs 13.6%; P = 0.054), lymph node metastasis (32.9%
vs 16.0%; P = 0.024), and an R1 resection (31.6% vs 13.6%;
P = 0.003) (Table 4). On multivariable analysis, lymph node
metastasis (HR 2.6; 95%CI, 1.4‐5.0; P = 0.004), R1 vs R0 margin
(HR 2.4; 95%CI, 1.1‐5.0; P = 0.025), and postoperative morbidity
(HR 1.4; 95%CI, 1.0‐2.0; P = 0.05) were independently associated
with early death among patients with MiVI (Table 5). In contrast,
among the 118 patients who survived longer than 18 months after
initial surgery, only lymph node metastasis was correlated with
late death (after 18 months) (HR 3.3; 95%CI, 1.5‐7.0; P = 0.002)
(Table 6).
TABLE 1 Clinicopathological characteristics and surgical treatments of patients undergoing curative resection for intrahepatic
cholangiocarcinoma stratified by vascular invasion status
No vascular
invasion (n = 691)
Microvascular
invasion (n = 249)
Macrovascular
invasion (n = 149) P value
Age, y 59 (50‐66) 63 (54‐71) 62 (52‐71) <0.001
Male gender 391 (57.5%) 132 (53.0%) 81 (54.4%) 0.422
Body mass index, kg/m2 25.3 (22.4‐28.0) 24.8 (22.6‐28.4) 24.6 (21.2‐27.0) 0.183
Carbohydrate antigen 19‐9, U/mL 43.5 (15.1‐180.2) 60.0 (20.0‐239.3) 60.9 (22.8‐382.0) 0.515
Carcinoembryonic antigen, ng/mL 2.4 (1.5‐4.0) 2.4 (1.4‐4.4) 2.4 (1.2‐6.0) 0.800
Tumor size, cm 6.0 (4.0‐8.0) 7.0 (4.5‐9.1) 6.5 (4.5‐9.0) 0.805
Multiple lesions (≥2) 108 (15.6%) 42 (16.9%) 22 (14.8%) 0.412
Perineural invasion 55 (8.0%) 81 (32.5%) 63(42.3%) <0.001
Direct invasion of adjacent organs 43 (6.2%) 12 (5.6%) 20 (13.4%) <0.001*
Biliary invasion 42 (6.1%) 51 (20.5%) 39 (26.2%) <0.001
Satellite lesions 123 (17.8%) 72 (28.9%) 47 (31.5%) <0.001
AJCC T stage <0.001
T1–2 578 (83.6%) 117 (47.0%) 61 (40.9%)
T3–4 64 (9.3%) 58 (23.3%) 44 (29.6%)
Missing 49 (7.1%) 74 (29.7%) 44 (29.5%)
AJCC N status <0.001*
N0 407 (61.2%) 94 (42.2%) 47 (44.3%)
N1–2 79 (11.9%) 51 (22.9%) 40 (37.7%)
Nx 179 (26.9%) 31 (35.0%) 19 (17.9%)
Histological grade 0.007
Well/ moderately differentiated 548 (79.3%) 162 (65.1%) 83 (55.7%)
Poorly to undifferentiated 94 (13.6%) 50 (20.1%) 22 (14.8%)
Missing 49 (7.1%) 37 (14.9%) 44 (29.5%)
R0 resection 636 (92.0%) 200 (80.3%) 118 (79.2%) <0.001
Major resection (≥3 segments) 139 (20.1%) 101 (40.6%) 87 (58.4%) <0.001*
Lymphadenectomy 242 (35.0%) 149 (59.8%) 71 (47.7%) <0.001
Intraoperative blood loss, mL 300 (200‐600) 525 (300‐1006) 800 (500‐1200) 0.002
Operation time, min 174 (108‐254) 310(210‐436) 301 (180‐640) 0.474
Postoperative morbidity 228 (33.0%) 106 (42.6%) 55 (36.9%) <0.001
Adjuvant chemo‐ and radiotherapy 171 (24.7%) 99 (39.8%) 57 (38.3%) <0.001
Abbreviation: AJCC, American Joint Committee on Cancer.
*indicates a P value less than 0.05 when compared between microvascular and macrovascular invasion groups.
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F IGURE 1 Overall (A) and disease‐free survival (B) of patients undergoing curative‐intent resection for intrahepatic cholangiocarcinoma
stratified by vascular invasion status. NoVI, none vascular invasion; MiVI, microvascular invasion; MaVI, macrovascular invasion [Color figure
can be viewed at wileyonlinelibrary.com]
TABLE 2 Risk factors for the overall survival of the whole cohort
Univariate analysis Multivariable analysis
Variable P value HR (95%CI) P value HR (95%CI)
Age ≥65, y 0.873 1.0 (0.9‐1.2)
Sex (M/F) 0.103 0.9 (0.7‐1.0)
Liver cirrhosis 0.877 1.0 (0.7‐1.3)
Tumor size >5 cm <0.001 1.7 (1.4‐2.1) <0.001 1.6 (1.3‐2.1)
Lymph node metastasis <0.001 1.6 (1.3‐1.9) <0.001 2.0 (1.6‐2.5)
Poorly to undifferentiated <0.001 1.7 (1.4‐2.1) <0.001 1.7 (1.4‐2.1)
Macrovascular invasion <0.001 1.7 (1.3‐2.1) 0.005 1.5 (1.1‐1.9)
Microvascular invasion 0.379 1.1 (0.9‐1.3)
Multiple tumors <0.001 1.9 (1.6‐2. 3) <0.001 1.7 (1.4‐2.0)
R1 Margin <0.001 1.8 (1.4‐2.3) <0.001 2.1 (1.6‐2.8)
Adjuvant chemo‐ and radiotherapy 0.762 1.0 (0.9‐1.2)
Abbreviations: CI, confidence intervals; HR, hazard ratios .
TABLE 3 Risk factors for disease‐free survival of the whole cohort
Univariate analysis Multivariable analysis
Variable P value HR (95%CI) P value HR (95%CI)
Age ≥65 y 0.458 0.9 (0.8‐1.1)
Sex (M/F) 0.991 1.0 (0.9‐1.2)
Liver cirrhosis 0.524 0.9 (0.7‐1.2)
Tumor size >5 cm <0.001 2.1 (1.7‐2.5) <0.001 2.0 (1.6‐2.5)
Lymph node metastasis 0.093 1.2 (1.0‐1.4) 0.005 1.3 (1.1‐1.6)
Poorly to undifferentiated <0.001 1.5 (1.2‐1.8) 0.022 1.3 (1.0‐1.6)
Macrovascular invasion 0.001 1.5 (1.2‐1.8) 0.022 1.4 (1.0‐1.8)
Microvascular invasion 0.002 1.4 (1.1‐1.6) <0.001 1.6 (1.3‐2.0)
Multiple tumors <0.001 1.8 (1.5‐2. 2) <0.001 1.6 (1.3‐2.5)
R1 Margin 0.009 1.4 (1.1‐1.8) 0.064 1.3 (1.0‐1.7)
Adjuvant chemo and radiotherapy <0.001 0.7 (0.6‐0.9) 0.381 0.9 (0.8‐1.1)
Abbreviations: CI, confidence intervals; HR, hazard ratios.
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4 | DISCUSSION
The AJCC 8th T classification incorporates vascular invasion as a
staging parameter for ICC, yet fails to distinguish the impact of
micro‐ vs macrovascular invasion.9 Whether long‐term survival of
patients undergoing curative‐intent surgery for ICC differs relative to
micro‐ vs macro‐vascular invasion has been poorly investigated. In
the present multi‐institutional study, both micro‐ and macrovascular
invasion of ICC were associated with advanced tumor characteristics
and stage. Compared with NoVI, the presence of MiVI increased the
risk of tumor recurrence, yet was not associated with worse long‐
term survival after surgery. In contrast, MaVI was a strong indicator
of both worse long‐term and disease‐free survival. The reason for
these disparate results was likely done to a higher proportion of MiVI
patients being candidates for repeat curative treatments at the time
of recurrence compared with MaVI patients. Of note, early death
among patients with MiVI was associated with tumor status (nodal
metastasis), surgical technique (R1 margin), and postoperative
complications. In contrast, the late death of patients was associated
only with biological factors such as the presence of lymph node
metastasis.
In the liver, small blood vessels are composed of an inner layer
of endothelial cells surrounded by a basal membrane. When tumor
cells in the liver have a sufficiently evolved phenotype, these cells
can invade either the portal vein or hepatic vein branches leading to
intrahepatic recurrence or systematic metastasis.10 MiVI has been
reported to be an independent predictor of tumor recurrence and
mortality after resection or transplantation of HCC.10-17 In turn,
MiVI is commonly utilized in the pathological assessment and
prognostic stratification of patients with HCC.10-17 Data in the
present study demonstrated that MiVI was an independent risk
factor for tumor recurrence, but not long‐term survival among
patients with ICC. Specifically, patients with only MiVI had the same
DFS compared with patients who had MaVI, as well as a comparable
recurrence pattern (intrahepatic recurrence: 58.2% vs 57.8%).
Interestingly, previous data had suggested that AJCC stage II
HCC patients with MiVI had similar outcomes as patients with
multiple tumors, implying that MiVI was a strong risk factor for
intrahepatic recurrence.13 In the present study, patients with ICC
and histologically confirmed MiVI or MaVI had a higher incidence of
perineural and biliary invasion, satellite lesions, advanced AJCC T
stages, nodal metastasis, and poor differentiation. Given the
association of vascular invasion with generally advanced disease,
patients with MiVI in the pathological liver specimen should be
closely surveilled for early detection and possible treatment of
any recurrence. To this point, several studies have reported that
F IGURE 2 A, Recurrence pattern after
curative‐intent resection for intrahepatic
cholangiocarcinoma among patients with
no vascular invasion (NoVI), microvascular
invasion (MiVI) or macrovascular invasion
(MaVI). B, The proportion of patients
receiving curative‐intent treatments for
recurrence in NoVI, MiVI and MaVI groups
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liver‐directed therapy for recurrences, such as surgical resection,
transarterial chemoembolization, and radiofrequency ablation,
might improve the prognosis of patients with recurrent ICC.22-24
In addition, although the effect of adjuvant chemotherapy on the
prognosis of ICC patients remains debatable, several studies have
demonstrated potential survival benefits of adjuvant chemotherapy
among “high‐risk” patients with advanced tumor characteristics,
such as nodal metastasis, advanced stages, or an inadequate
margin.1,25,26 As such, patients with MiVI should similarly be
considered for appropriate adjuvant therapy.
While DFS was comparable among patients with MiVI and MaVI,
median OS was longer among patients with MiVI (39.0 vs 21.0
months). In fact, despite differences in DFS, OS of patients with MiVI
was even comparable to the OS of patients who had NoVI (39.0 vs
45.0 months). While the reasons for these differences were
undoubtedly multifactorial, these findings can be explained in part
by the fact that patients with MiVI had a higher utilization of curative
treatment of recurrences than patients with MaVI (17.7% vs 7.0%).
While data on the extent/burden of tumor recurrence were not
available, the higher utilization of repeat curative‐intent surgery
among patients with MiVI strongly implied a less aggressive
phenotype of intrahepatic‐only recurrence among patients with MiVI
vs MaVI. To this point, median OS after the first recurrence among
patients with MiVI was more than double that of patients with MaVI
(17.0 vs 8.0 months).
In examining survival, patients with MiVI had a comparable
prognosis as patients with MaVI within the first 1 to 2 years after
surgery yet diverged at 18 to 24 months. Previous work from our
group had suggested that the timing of early vs late recurrence
among patients with ICC could be defined empirically using a cut‐
off of about 2 years.6 In addition, among patients who did recur,
the overwhelming majority recurred early. Similarly, in the present
study, we were able to identify two prognostic cohorts among
patients who had MiVI. In particular, there was a subset of patients
who experienced early recurrence and death within the first 18 to
24 months after surgery. Interestingly, on multivariable analysis,
factors associated with early mortality included multiple tumors
(26.6% vs 13.6%; P = 0.054), lymph node metastasis (32.9% vs
16.0%; P = 0.024), and an R1 resection (31.6% vs 13.6%;
P = 0.003).5,27-31 In contrast, among patients who were late
survivors, the only factor associated with prognosis was lymph
node metastasis, as patients with the nodal disease had a three‐
fold increased risk of late death (HR 3.3; 95% CI 1.5‐7.0;
P = 0.002). Lymph node status has previously been documented
as one of the strongest prognostic factors associated with
outcomes among patients with ICC.32-38 The present study
highlights how lymph node status remained a strong indicator of
prognosis even among patients with other risk factors such as
MiVI. As such, routine lymphadenectomy to assess the nodal basin
should be performed at the time of surgery to obtain important
prognostic information, guide adjuvant therapy recommendations,
as well as possibly prevent hilar nodal recurrence.34,39-42
Several limitations need to be considered when interpreting the
present study. While the multicenter nature of the study undoubt-
edly increased sample size and analytical power, selection bias and
variation in treatment strategies were possible. For example, patient
selection for surgical resection has evolved over time and surgical
approaches may have varied across the different centers. In addition,
the diagnosis of MiVI was largely dependent on sample collection and
histological examination. Therefore, it was possible that some
variability in reporting of MiVI may have occurred, although this
was likely low as the participating hospitals were major HPB centers
with expertise in hepatopathology.
TABLE 4 Clinical and pathological characteristics of early dead







(n = 118) P value
Age, years 63 (52‐71) 63 (56‐70) 0.581




Tumor Size, cm 7.0 (5.0‐8.7) 6.5 (4.0‐9.5) 0.576
Multiple lesions (≥2) 21 (26.6%) 16 (13.6%) 0.054
Perineural invasion 30 (38.0%) 36 (30.5%) 0.323
Direct invasion of adjacent
organs
4 (5.1%) 5 (4.2%) 0.997
Biliary invasion 16 (20.3%) 22 (18.6%) 0.676
Satellite lesions 29 (36.7%) 28 (23.7%) 0.063
AJCC tumour category 0.455
T1–2 44 (55.7%) 55 (46.6%)
T3–4 23 (29.1%) 23 (19.5%)
Missing 12 (15.2%) 40 (33.9%)
AJCC node category 0.024
N0 28 (35.4%) 46 (46.0%)
N1–2 26 (32.9%) 16 (16.0%)




49 (62.0%) 78 (66.1%)
Poorly to
undifferentiated
22 (27.8%) 18 (15.3%)
Missing 8 (10.1%) 22 (18.6%)
R0 resection 54 (68.4%) 102 (86.4%) 0.003











31 (39.2%) 49 (41.5%) 0.749
Abbreviation: AJCC, American Joint Committee on Cancer.
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In conclusion, among patients undergoing curative resection for
ICC, roughly one out of five patients had MiVI on histological
examination, while one out of ten patients had the macrovascular
invasion. MiVI was associated with advanced tumor characteristics,
and thus a higher risk of tumor recurrence. Risk of early death among
patients with MiVI was associated with tumor and surgical factors,
while the risk of late death was largely impacted by lymph node
status. MiVI status should be routinely documented in the pathology
report of patients undergoing resection of ICC as these data have
prognostic and possibly treatment‐related implications.
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